(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/278480 A1

(51) International Patent Classification:
*C07K 16/28* (2006.01) *A61K 39/395* (2006.01)

(21) International Application Number:
PCT/US2022/035363

(22) International Filing Date:
28 June 2022 (28.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/216,276 29 June 2021 (29.06.2021) US

(71) Applicant: **ELPIS BIOPHARMACEUTICALS** [US/US]; 128 Spring Street, Lexington, Massachusetts 02421 (US).

(72) Inventors: **ZHAO, Kehao**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **CHEN, Yan**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **NGUYEN, Jenna**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **SUBRAMANIAM, Suga**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US). **JIANG, Ning**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US).

(74) Agent: **CHEN, Yahua** et al.; The McDermott Building, 500 North Capitol Street, N.W., Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-NECTIN4 ANTIBODIES AND MULTI-SPECIFIC PROTEIN COMPLEXES COMPRISING SUCH

(57) Abstract: Antibodies that binds Nectin Cell Adhesion Molecule 4 (nectin-4) and multi-specific protein complexes comprising such anti-nectin4 antibodies, at least one additional antibody moiety binding to another target, and/or at least one cytokine moiety. Also provided herein are pharmaceutical compositions comprising such and uses thereof.

WO 2023/278480 A1